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Introduction 
Asthma is a chronic inflammatory disease of the airways 
characterized by reversible airway constriction and airway 
hyperresponsiveness. It is a common disease, affecting 
S-IO% of adults. Chronic inflammatory reactions are 
central to the disease process and underly the functional 
airway abnormalities in asthma. Chronically inflamed 
airways are hyperresponsive and become obstructed as 
airflow is limited by smooth muscle contraction, oedema, 
excess mucus production and infiltrating inflammatory cells. 
Changes in the airways in asthma have been assessed in a 
number of ways. Post-mortem examination of the lungs of 
patients who have died with asthma permits direct analysis 
of the cell types infiltrating the airways and the structure 
and composition of the airway wall. Direct in vivo sampling 
techniques such as biopsies, induced sputum, bronchoal- 
veolar lavage (BAL), bronchial washes and bronchial 
brushing have proved useful in providing important 
information on the airway changes that characterize 
asthma. 
Most studies have focused on the large conducting 
airways, as these are more accessible both for histological 
examination and in vivo sampling. The small airways (those 
less than 2 mm diameter) contribute only 10% of total 
airway resistance and have been termed the ‘silent zone’ (1). 
Due to difficulty of sampling and lack of specific tests for 
small airways function, changes in the small airways in 
asthma have been largely under-evaluated. More recently, 
however, sensitive methods of airway analysis, such as 
high-resolution computed tomography (HRCT), have 
shown that the inflammatory and structural changes in 
asthma occur in both the large and small airways (2). 
Moreover, the low resistance of the small airways means 
that they can be extensively damaged and severely 
obstructed before the patient experiences any symptoms 
(3). The growing importance of small involvement in the 
pathogenesis of asthma is, therefore, becoming clearer. 
Cellular changes in asthma 
Inflammation in asthma is a multicellular process, involving 
eosinophils, neutrophils, mast cells, macrophages and 
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T-lymphocytes, with eosinophilic infiltration being the 
most striking feature. Recent investigations have indicated 
that eosinophilic infiltration of the bronchial mucosa occurs 
in both large and small airways (4,5). More recently, Haley 
et al. (6) analysed the distribution of eosinophils and ‘other 
leukocytes (CD45+ cells) in the airways in patients who 
died from asthma compared with those who died from 
cystic fibrosis. They showed that, while cellular infiltration 
was found throughout the respiratory tract in both diseases, 
in asthma the distribution differed between the large and 
small airways. Cellular infiltration of the outer section of 
the airway wall, between the smooth muscle and alveolar 
attachments, was evident in the small airways, while the 
infiltrating cells in the large airways were predominantly 
found in the inner section of the airway wall, between the 
smooth muscle and basement membrane (Fig. 1). This 
differential distribution of inflammatory cells was not seen 
in the lungs of patients with cystic fibrosis, pointing to a 
particular involvement of small airway inflammation in 
asthma. 
Changes in the bronchial epithelium 
Pro-inflammatory cytokines released from infiltrating cells 
prolong and maintain the inflammatory process, resulting 
in chronic, severe damage to the airway epithelium (7). The 
importance of damage to the bronchial epithelium in 
asthma is strongly indicated by the extent of epithelial 
disruption seen in asthmatic airways at post-mortem (8) or 
by bronchoscopy (9,lO) and by the presence of large 
numbers of epithelial cell &mps in asthmatic sputum, 
especially during exacerbations (11). Normal bronchial 
epithelium is composed of a basal cell layer with a 
suprabasal layer of ciliated columnar cells and goblet cells. 
When the epithelium is damaged it is the columnar cells 
that are predominantly lost. In individuals with asthma, 
loss of columnar cells from the bronchial epithelium is 
markedly increased compared with non-asthmatic subjects 
(12). Although, with fibre-optic biopsies, this has been 
attributed to artefact, recent studies rising cell surface 
markers such as CD44 and EGF receptors indicate pre- 
biopsy disruption (13,14). 
Chronic inflammatory reactions mediated by eosinophils 
and other infiltrating leukocytes are a significant cause of 
damage ‘to the bronchial epithelium in asthma. It is 
apparent, ..that the epithelium also undergoes phenotypic 
changes, which are of at least equal importance to 
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FIG. 1. Schematic representation of the cascade of events 
initiated by epithelial damage, leading to myofibroblast 
activation and propagation of structural changes 
throughout the airway wall [reproduced with permission 
from Holgate et al. J Allergy Clin Imrnur~ol 2000; 105: 
193-204 (17)]. 
infiltrating leukocytes in the pathogenesis of the disease. In 
asthma, the airway epithelium has been found to be a 
significant source of pro-inflammatory chemokines and 
cytokines (15,16). Widespread increases in expression of the 
epidermal growth factor receptor, a pivotal regulator of 
epithelial cell function and repair, are seen in the bronchial 
epithelium of asthmatic patients (14,17). The alterations in 
airway epithelial structure and function become amplified 
throughout the airway wall, resulting in the range of 
changes in fibroblasts, smooth muscle cells and other cell 
types, known as airway remodelling. 
Airway remodelling 
Post-mortem analysis of the airways of patients who have 
died with asthma demonstrate that the airway wall 
is thickened and the lumen reduced. HRCT in asthmatic 
patients confirm that these changes occur in both the 
large and small airways (18). The driving force behind 
airway remodelling is the release of chemokines and 
cytokines by infiltrating cells and the airway epithelium, 
which maintains the airway wall smooth muscle cells 
and myofibroblasts in a state of activation (17). Activated 
myofibroblasts increase their production of matrix proteins 
including collagens, fibronectin and tenascin (19,20) 
and matrix deposition beneath the basement membrane 
results in thickening of the airway wall. Airway wall 
thickening has been documented throughout the airways 
in asthma, including the small airways (21,22). Activated 
myofibroblasts also secrete growth-promoting cytokines, 
which cause an increase in the smooth muscle mass 
(23,24) resulting in an exaggerated effect of the spiralling 
smooth muscle on reduction of the airway lumen (Fig. 1). 
Airway remodelling can thus be seen as a multi-step 
process initiated by epithelial damage and inflammatory 
reactions that are then propagated and amplified by 
phenotypically altered airway epithelium, resulting in 
narrowing of the large and small airways and airflow 
limitation (Fig. 2). 
Mucous plugging 
The narrowing of the airways caused by airway remodelling 
and hyperreactivity is naturally a major cause of airflow 
limitation, but there are other consequences of inflamma- 
tion in the airways that contribute to this process. Secretion 
of mucus from goblet cells in the airway epithelium 
becomes disordered in patients with asthma, as a con- 
sequence of inflammatory reactions in the airways. Neu- 
trophil elastase has been shown to be a mediator of goblet 
cell secretion (25), but other mediators released from 
infiltrating inflammatory cells or epithelial cells, including 
transforming growth factor-a (TGFa), EGF and interleu- 
kins, such as IL-4, IL-9 and IL-13, are also likely to play a 
role in stimulation of mucus secretion. Excess mucus, 
inflammatory cells and columnar cells shed from damaged 
epithelium can form a tenacious plug that may completely 
block airflow, particularly in the smaller airways. Mucous 
plugging has been identified in the smallest airways, which 
lack mucus-secreting goblet cells, following post-mortem 
examination of patients who have died with asthma (18,26) 
(Fig. 3). 
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FIG. 2. Schematic drawing of ‘inner’ and ‘outer’ airway 
wall regions. [Reproduced with permission from Haley er 
al. Am J Respir Crit Care Med 1998; 158: 565-572 (6)]. 
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FIG. 3. Airway remodelling in asthma in the relative absence of inflammation. Note the mucous occlusion of the lumen of 
this small conducting airway. 
Nocturnal asthma 
In patients with nocturnal asthma, respiratory symptoms 
worsen considerably at night. Studying inflammatory 
changes in nocturnal asthma, therefore, provides a model 
to relate these changes to worsening of the condition in a 
naturally occurring situation. It is clear that the inflamma- 
tory response is considerably greater at night in patients 
who experience nocturnal asthma (27,28). Analyses of 
transbronchial and endobronchial biopsies have shown that 
the overnight decrease in lung function correlates with 
increased numbers of eosinophils and CD4+ lymphocytes in 
the alveolar tissue (29). Furthermore, nocturnal increases in 
eosinophils, lymphocytes and macrophages were found in 
the peribronchial alveolar tissue, but not in the proximal 
airways (29,30), indicating that inflammation in the 
peripheral airways and alveoli is responsible for the acute 
worsening of the condition. 
Conclusions 
Airflow limitation in asthma results from the maintenance 
of chronic inflammatory reactions in the airways. Eosino- 
phils, neutrophils, mast cells, lymphocytes and macro- 
phages, as well as myofibroblasts, epithelial cells and 
smooth muscle cells, contribute to the inflammation, 
releasing cytokines and other mediators that maintain and 
prolong the inflammatory process. The conseque,nces of 
chronic airway inflammation include increased epithelial 
fragility, airway wall thickening and narrowing of the 
lumen. This process of airway remodelling, which ulti- 
mately leads to airflow obstruction, is initiated either by 
inflammation-induced epithelial damage or increased sus- 
ceptibility of the epithelium to damage (premature apop- 
tosis-programmed cell death) that leads to activation of 
myofibroblasts in the airway wall causing excess matrix 
deposition and increased smooth muscle mass. 
It is clear that the inflammatory reactions and epithelial 
damage that occur in asthma take place in both the large 
and small airways, and may begin from an early age (31). 
Inflammatory cell infiltration and airway remodelling have 
been documented in airways smaller than 2 mm diameter. 
Furthermore, studies in nocturnal asthma suggest that the 
acute alteration in respiratory symptoms at night is 
associated with cellular infiltration preferentially in the 
alveolar tissue rather than the proximal airways. The 
smaller airways, which have been largely under-evaluated in 
asthma should now be considered as an important site of 
inflammation and remodelling leading to airflow limitation 
in asthma. 
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